Literature DB >> 29507797

Surgery for malignant pleural mesothelioma: an international guidelines review.

Sara Ricciardi1, Giuseppe Cardillo2, Carmelina Cristina Zirafa3, Francesco Carleo2, Francesco Facciolo4, Gabriella Fontanini5, Luciano Mutti6, Franca Melfi3.   

Abstract

Currently there is no universally accepted surgical therapy for malignant pleural mesothelioma (MPM). The goal of surgery in this dismal disease is a macroscopic complete resection (MCR) and there are two types of intervention with a curative intent. At one side, there is the extrapleural pneumonectomy (EPP) which consists in an en-bloc resection of the lung, pleura, pericardium and diaphragm and at the other side, there is pleurectomy/decortication (P/D) a lung-sparing surgery. Initially, EPP was considered the only surgical option with a curative aim, but during the decades P/D have acquired a role of increasing importance in MPM therapy. Several randomized prospective trials are required to establish the best strategy in the treatment of pleural mesothelioma. Although which is the best surgical option remains unclear, the International Mesothelioma Interest Group (IMIG), recently have stated that the type of surgery depends on clinical factors and on individual surgical judgment and expertise. Moreover, according to the current evidence, the surgery should be performed in high-volume centres within multimodality protocols. The aim of this study is to examine the currently available international guidelines in the surgical diagnosis and treatment of MPM.

Entities:  

Keywords:  Pleural mesothelioma; guidelines; multimodality treatment; review; surgery

Year:  2018        PMID: 29507797      PMCID: PMC5830571          DOI: 10.21037/jtd.2017.10.16

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  40 in total

1.  Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.

Authors:  Ottavio Rena; Caterina Casadio
Journal:  Lung Cancer       Date:  2012-01-11       Impact factor: 5.705

2.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

3.  Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.

Authors:  Loïc Lang-Lazdunski; Andrea Bille; Rohit Lal; Paul Cane; Emma McLean; David Landau; Jeremy Steele; James Spicer
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

Review 4.  A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.

Authors:  Elaine Teh; Francesca Fiorentino; Carol Tan; Tom Treasure
Journal:  J R Soc Med       Date:  2011-02       Impact factor: 5.344

5.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

Review 6.  Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.

Authors:  Andrea S Wolf; Raja M Flores
Journal:  Thorac Surg Clin       Date:  2016-08       Impact factor: 1.750

7.  Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.

Authors:  Hasan Fevzi Batirel; Muzaffer Metintas; Hale Basak Caglar; Guntulu Ak; Perran Fulden Yumuk; Bedrettin Yildizeli; Mustafa Yuksel
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-09       Impact factor: 5.209

8.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

9.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  10 in total

1.  Serum and Pleural Soluble Cell Adhesion Molecules in Mesothelioma Patients: A Retrospective Cohort Study.

Authors:  Sofia Tsagkouli; Ioannis G Kyriakoulis; Konstantinos G Kyriakoulis; Eleni Fyta; Alexandros Syrigos; Petros Bakakos; Adrianni Charpidou; Elias Kotteas
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

2.  Depression and Complicated Grief, and Associated Factors, of Bereaved Family Members of Patients Who Died of Malignant Pleural Mesothelioma in Japan.

Authors:  Yasuko Nagamatsu; Yumi Sakyo; Edward Barroga; Riwa Koni; Yuji Natori; Mitsunori Miyashita
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

Review 3.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Authors:  Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

4.  PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.

Authors:  Marcella Barbarino; Daniele Cesari; Maria Bottaro; Luca Luzzi; Asadoor Namagerdi; Franca Maria Bertolino; Cristiana Bellan; Fabrizio Proietti; Pasquale Somma; Mariacarolina Micheli; Maria Margherita de Santi; Raffaella Guazzo; Luciano Mutti; Luigi Pirtoli; Piero Paladini; Paola Indovina; Antonio Giordano
Journal:  J Cell Mol Med       Date:  2020-04-17       Impact factor: 5.310

5.  Surgical staging and resection of malignant pleural mesothelioma.

Authors:  Lawrence B Brown; Frank Corl; Shanda H Blackmon
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 3.005

Review 6.  Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Authors:  Melanie Vogl; Anna Rosenmayr; Tomas Bohanes; Axel Scheed; Milos Brndiar; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

Review 7.  A Glimpse in the Future of Malignant Mesothelioma Treatment.

Authors:  Gaetano Pezzicoli; Mimma Rizzo; Martina Perrone; Silvia Minei; Luciano Mutti; Camillo Porta
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

Review 8.  An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.

Authors:  Alexander Davis; Helen Ke; Steven Kao; Nick Pavlakis
Journal:  Lung Cancer (Auckl)       Date:  2022-03-02

9.  Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Saadullah Khattak; Muhammad Usman Akbar; Muhammad Badar; Nazeer Hussain Khan; Lu Zhang; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Cells       Date:  2022-09-19       Impact factor: 7.666

10.  Improving outcomes in malignant pleural mesothelioma in an integrated health care system.

Authors:  Stephanie Ossowski; Yun-Yi Hung; Kian Banks; Diana Hsu; Lisa Herrinton; Simon Ashiku; Ashish Patel; J Marie Suga; Jeffrey B Velotta
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.